

CHEMISTRY

AN ASIAN JOURNAL

Supporting Information

© Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, 2014

Synthesis of Quinazolines and Tetrahydroquinazolines: Copper-Catalyzed Tandem Reactions of 2-Bromobenzyl Bromides with Aldehydes and Aqueous Ammonia or Amines

Xuesen Fan,* Bin Li, Shenghai Guo, Yuanyuan Wang, and Xinying Zhang^[a]

asia_201301296_sm_miscellaneous_information.pdf

Supporting Information

Table of Contents

I. General Experimental Information	P2
II. Synthetic procedures and spectroscopic data	P3-14
III. Copies of ^1H and ^{13}C NMR spectra of 4a-4t	P15-34
IV. Copies of ^1H and ^{13}C NMR spectra of 5a-5r	P35-52
V. Copies of ^1H and ^{13}C NMR spectra of 7	P53
VI. Copies of ^1H and ^{13}C NMR spectra of 8	P54
VII. References	P55


I. General Experimental Information

All the commercial reagents and solvents were used without further purification. Melting points were recorded with a micro melting point apparatus and uncorrected. ^1H and ^{13}C NMR spectra were recorded at 400 and 100 MHz, respectively. High-resolution mass spectra (HRMS) were obtained by using a MicrOTOF mass spectrometer. All reactions were monitored by thin-layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm) and components were visualized by observation under UV light (254 and 365 nm).

II. Synthetic procedures and spectroscopic data

General procedure for the preparation of quinazoline 4.

To a tube containing a solution of 2-bromobenzyl bromide **1** (0.5 mmol) in DMSO (2 mL) were added aldehyde **2** (0.6 mmol), Cu(OAc)₂ (0.05 mmol), DMAP (0.15 mmol) and 26% aqueous ammonia **3** (1 mL). Then, the tube was sealed and the mixture was stirred at 80 °C under air atmosphere for 24 h. After being cooled to room temperature, the reaction was quenched with aqueous NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with H₂O and brine, and then dried over anhydrous Na₂SO₄. The solvent was evaporated under vacuum and the crude product was purified by chromatography on silica-gel to afford quinazoline derivatives **4**.



2-Phenylquinazoline (4a): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (71 mg, 68%), mp 101-103 °C (lit¹. mp 102-103 °C); ¹H NMR (400 MHz, CDCl₃) δ: 7.51-7.55 (m, 3H; 11-H, 12-H and 13-H), 7.56-7.63 (m, 1H; 6-H), 7.89-7.94 (m, 2H; 5-H and 7-H), 8.09 (d, *J* = 8.8 Hz, 1H; 8-H), 8.61-8.64 (m, 2H; 10-H and 14-H), 9.47 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.6 (C-4a), 127.1 (C-5), 127.3 (C-6), 128.6 (C-10 and C-14), 128.7 (C-8, C-11 and C-13), 130.6 (C-12), 134.1 (C-7), 138.1 (C-9), 150.8 (C-8a), 160.5 (C-4), 161.1 (C-2). IR (KBr) ν = 2921, 1601, 1532, 1396, 731 cm⁻¹. MS: m/z 207 (MH)⁺.

2-p-Tolylquinazoline (4b): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (72 mg, 64%), mp 106-108 °C (lit¹. mp 107-109 °C); ¹H NMR (400 MHz, CDCl₃) δ: 2.45 (s, 3H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.57-7.61 (m, 1H), 7.87-7.92 (m, 2H), 8.06-8.08 (m, 1H), 8.51 (d, *J* = 8.0 Hz, 2H), 9.45 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 21.5, 123.5, 127.0, 127.1, 128.5, 128.6, 129.4, 134.0, 135.3, 140.9, 150.8, 160.5, 161.2. IR (KBr) ν = 2920, 1588, 1551, 1379, 725 cm⁻¹. MS: m/z 221 (MH)⁺.

2-(4-Bromophenyl)quinazoline (4c): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (103 mg, 72%), mp 124-126 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.61-7.67 (m, 3H), 7.92 (t, *J* = 8.0 Hz, 2H), 8.07 (d, *J* = 8.4 Hz, 1H), 8.50 (d, *J* = 8.0 Hz, 2H), 9.44 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.7, 125.4, 127.2, 127.5, 128.6, 130.2, 131.8, 134.3, 137.0, 150.7, 160.1, 160.6. IR (KBr) ν = 3030,

1522, 1480, 1402, 755 cm⁻¹. MS: m/z 285 (MH)⁺. HRMS (ESI) calcd for C₁₄H₁₀BrN₂: 285.0027 [M+H], found: 285.0015.

2-(4-Nitrophenyl)quinazoline (4d): Eluent: petroleum ether-ethyl acetate (10:1); yellow solid (94 mg, 74%), mp 217-219 °C (lit². mp 218-219 °C); ¹H NMR (400 MHz, CDCl₃) δ: 7.54 (q, *J* = 13.6 Hz, 2H), 7.61-7.50 (m, 1H), 7.91-7.95 (m, 2H), 8.12 (d, *J* = 8.8 Hz, 1H), 8.62-8.64 (m, 2H), 9.49 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.6, 127.2, 127.4, 128.6, 128.66, 128.69, 130.8, 134.3, 137.8, 150.7, 160.5, 161.0. IR (KBr) ν = 2926, 1605, 1504, 1322, 742 cm⁻¹. MS: m/z 252 (MH)⁺.

4-(Quinazolin-2-yl)benzonitrile (4e): Eluent: petroleum ether-ethyl acetate (10:1); yellow solid (77 mg, 66%), mp 193-196 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.69 (t, *J* = 7.6 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 2H), 7.94-7.99 (m, 2H), 8.11 (d, *J* = 7.6 Hz, 1H), 8.75 (d, *J* = 8.4 Hz, 2H), 9.50 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 113.8, 118.9, 123.9, 127.2, 128.2, 128.8, 129.0, 132.4, 134.5, 142.2, 150.6, 159.1, 160.7. IR (KBr) ν = 2924, 1598, 1515, 1396, 742 cm⁻¹. MS: m/z 232 (MH)⁺. HRMS (ESI) calcd for C₁₅H₁₀N₃: 232.0874 [M+H], found: 232.0871.

2-(4-(Trifluoromethyl)phenyl)quinazoline (4f): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (104 mg, 75%), mp 135-137 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.66 (t, *J* = 7.6 Hz, 1H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.92-7.96 (m, 2H), 8.10 (d, *J* = 8.4 Hz, 1H), 8.73 (d, *J* = 8.4 Hz, 2H), 9.48 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.8, 125.48, 125.52, 125.56, 125.60, 127.2, 127.9, 128.8, 128.9, 134.5, 141.2, 150.6, 159.6, 160.6. IR (KBr) ν = 2924, 1553, 1326, 1070, 804 cm⁻¹. MS: m/z 275 (MH)⁺. HRMS (ESI) calcd for C₁₅H₁₀F₃N₂: 275.0796 [M+H], found: 275.0795.

2-m-Tolylquinazoline (4g): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (75 mg, 67%), mp 114-116°C; ¹H NMR (400 MHz, CDCl₃) δ: 2.49 (s, 3H), 7.33 (d, *J* = 7.2 Hz, 1H), 7.42-7.46 (m, 1H), 7.60 (t, *J* = 7.2 Hz, 1H), 7.88-7.92 (m, 2H), 8.09 (d, *J* = 8.0 Hz, 1H), 8.41-8.43 (m, 2H), 9.46 (d, *J* = 1.2 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 21.6, 123.6, 125.8, 127.16, 127.24, 128.6, 129.1, 131.5, 134.1, 138.0, 138.3, 150.8, 160.5, 161.2. IR (KBr) ν = 2916, 1615, 1502, 1396, 721 cm⁻¹. MS: m/z 221 (MH)⁺. HRMS (ESI) calcd for C₁₅H₁₃N₂: 221.1078 [M+H], found: 221.1065.

2-(3-Fluorophenyl)quinazoline (4h): Eluent: petroleum ether-ethyl acetate (20:1); white solid (75 mg, 66%), mp 93-95 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.17-7.22 (m, 1H), 7.46-7.51 (m, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.88-7.92 (m, 2H), 8.07 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.41 (d, J = 7.6 Hz, 1H), 9.43 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 115.3, 115.5, 117.4, 117.6, 123.7, 124.17, 124.21, 127.2, 127.6, 128.7, 130.0, 130.1, 134.3, 140.5, 150.6, 159.78, 159.82, 160.6, 162.1, 164.5. IR (KBr) ν = 2926, 1584, 1516, 1358, 726 cm⁻¹. MS: m/z 225 (MH)⁺. HRMS (ESI) calcd for C₁₄H₁₀FN₂: 225.0828 [M+H], found: 225.0815.

2-(3-Bromophenyl)quinazoline (4i): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (92 mg, 64%), mp 153-155 °C (lit². mp 153-155 °C); ¹H NMR (400 MHz, CDCl₃) δ: 7.39 (t, J = 8.0 Hz, 1H), 7.63 (t, J = 7.2 Hz, 2H), 7.91 (t, J = 7.6 Hz, 2H), 8.07 (d, J = 8.4 Hz, 1H), 8.55 (d, J = 8.0 Hz, 1H), 8.78 (s, 1H), 9.44 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.0, 123.8, 127.1, 127.2, 127.7, 128.7, 130.2, 131.6, 133.5, 134.4, 140.1, 150.6, 159.6, 160.6. IR (KBr) ν = 3021, 1598, 1512, 1402, 761 cm⁻¹. MS: m/z 285 (MH)⁺.

2-(2-Chlorophenyl)quinazoline (4j): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (81mg, 67%), mp 68-70 °C (lit². mp 69-70 °C); ¹H NMR (400 MHz, CDCl₃) δ: 7.51-7.56 (m, 2H), 7.62 (t, J = 7.2 Hz, 1H), 7.90-7.95 (m, 2H), 8.10 (d, J = 8.8 Hz, 1H), 8.62 (d, J = 6.8 Hz, 2H), 9.48 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.6, 127.1, 127.3, 128.6, 128.7, 128.9, 130.6, 134.1, 138.0, 150.8, 160.5, 161.1. IR (KBr) ν = 2924, 1608, 1504, 12884, 745 cm⁻¹. MS: m/z 241 (MH)⁺.

2-(2-Bromophenyl)quinazoline (4k): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (76 mg, 53%), mp 72-74 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.51-7.56 (m, 2H), 7.59 (t, J = 7.6 Hz, 1H), 7.89 (t, J = 8.4 Hz, 2H), 8.08 (d, J = 8.4 Hz, 1H), 8.62 (d, J = 8.4 Hz, 2H), 9.45 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 123.6, 127.2, 127.3, 128.60, 128.64, 128.7, 130.6, 134.2, 138.0, 150.8, 160.5, 161.1. IR (KBr) ν = 3062, 1550, 1485, 1402, 772 cm⁻¹. MS: m/z 285 (MH)⁺. HRMS (ESI) calcd for C₁₄H₁₀BrN₂: 285.0027 [M+H], found: 285.0022.

2-(2-Nitrophenyl)quinazoline (4l): Eluent: petroleum ether-ethyl acetate (10:1); yellow solid (91 mg, 72%), mp 93-95 °C; ¹H NMR (400 MHz, CDCl₃) δ: 7.51-7.56 (m, 2H), 7.60-7.64 (m, 1H), 7.89-

7.94 (m, 2H), 8.10 (d, J = 8.0 Hz, 1H), 8.61-8.63 (m, 2H), 9.48 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 123.6, 127.2, 127.3, 127.9, 128.6, 128.7, 130.6, 133.17, 133.22, 134.2, 138.0, 150.8, 160.5, 161.1. IR (KBr) ν = 2914, 1612, 1504, 1318, 736 cm^{-1} . MS: m/z 252 (MH^+). HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{10}\text{N}_3\text{O}_2$: 252.0773 [M+H], found: 252.0788.

2-(Pyridin-4-yl)quinazoline (4m): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (38 mg, 37%), mp 124-126 °C; ^1H NMR (400 MHz, CDCl_3) δ : 7.69 (t, J = 7.6 Hz, 1H), 7.96 (t, J = 8.4 Hz, 2H), 8.12 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 6.0 Hz, 2H), 8.80 (d, J = 5.2 Hz, 2H), 9.50 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 122.4, 124.2, 127.2, 128.4, 128.9, 134.6, 145.4, 150.4, 150.6, 158.9, 160.8. IR (KBr) ν = 2921, 1617, 1544, 1402, 759 cm^{-1} . MS: m/z 208 (MH^+). HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{10}\text{N}_3$: 208.0874 [M+H], found: 208.0879.

Quinazoline (4n): Eluent: petroleum ether-ethyl acetate (5:1); yellow syrup (17 mg, 27%); ^1H NMR (400 MHz, CDCl_3) δ : 7.61-7.65 (m, 1H), 7.87-7.91 (m, 2H), 8.02 (d, J = 8.4 Hz, 1H), 9.30 (s, 1H), 9.37 (s, 1H). IR (KBr) ν = 3053, 1621, 1549, 1402, 756 cm^{-1} . ^{13}C NMR (100 MHz, CDCl_3) δ : 125.1, 127.2, 128.0, 128.4, 134.2, 150.0, 155.2, 160.2. MS: m/z 131 (MH^+).

5-Chloro-2-phenylquinazoline (4o): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (79 mg, 65%), mp 81-83 °C; ^1H NMR (400 MHz, CDCl_3) δ : 7.53-7.57 (m, 3H), 7.62 (d, J = 7.6 Hz, 1H), 7.78-7.82 (m, 1H), 8.01 (d, J = 8.0 Hz, 1H), 8.62-8.64 (m, 2H), 9.84 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 121.4, 127.2, 127.8, 128.7, 128.8, 131.0, 131.9, 133.9, 137.5, 151.9, 157.9, 161.7. IR (KBr) ν = 2924, 1566, 1548, 1380, 701 cm^{-1} . MS: m/z 241 (MH^+). HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{10}\text{ClN}_2$: 241.0532 [M+H], found: 241.0523.

Methyl 2-phenylquinazoline-6-carboxylate (4p): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (91 mg, 68%), mp 179-182 °C; ^1H NMR (400 MHz, CDCl_3) δ : 4.02 (s, 3H), 7.55-7.56 (m, 3H), 8.14 (d, J = 8.8 Hz, 1H), 8.49 (d, J = 8.8 Hz, 1H), 8.64-8.65 (m, 2H), 8.69 (s, 1H), 9.57 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 52.6, 122.8, 128.7, 128.8, 128.9, 130.2, 131.3, 133.7, 137.4, 152.7,

161.7, 162.7, 165.9. IR (KBr) ν = 2948, 1719, 1627, 1439, 1254, 703 cm⁻¹. MS: m/z 265 (MH)⁺. HRMS (ESI) calcd for C₁₆H₁₃N₂O₂: 265.0977 [M+H], found: 265.0980.


6-Methoxy-2-phenylquinazoline (4q): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (71 mg, 60%), mp 119-122 °C (lit¹. mp 120-122 °C); ¹H NMR (400 MHz, CDCl₃) δ : 3.96 (s, 3H), 7.40 (d, *J* = 3.6 Hz, 1H), 7.48-7.56 (m, 4H), 7.99 (d, *J* = 8.8 Hz, 1H), 8.57 (dd, *J*₁ = 8.0 Hz, *J*₂ = 2.0 Hz, 2H), 9.36 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 55.7, 103.9, 124.5, 127.2, 128.2, 128.6, 130.1, 130.2, 138.2, 147.0, 158.3, 158.8, 159.4. IR (KBr) ν = 2924, 1604, 1532, 1386, 746 cm⁻¹. MS: m/z 237 (MH)⁺.

2-Phenylbenzo[*h*]quinazoline (4r): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (81 mg, 63%), mp 135-137 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.54-7.61 (m, 3H), 7.74 (d, *J* = 8.8 Hz, 1H), 7.80-7.87 (m, 3H), 7.93-7.95 (m, 1H), 8.76-8.78 (m, 2H), 9.42 (s, 1H), 9.44-9.46 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 121.5, 123.0, 125.0, 127.5, 128.1, 128.56, 128.60, 128.7, 130.2, 130.3, 130.7, 135.6, 138.2, 150.9, 158.5, 161.0. IR (KBr) ν = 2924, 1618, 1552, 1402, 739 cm⁻¹. MS: m/z 257 (MH)⁺. HRMS (ESI) calcd for C₁₈H₁₃N₂: 257.1078 [M+H], found: 257.1069.

6-(4-Chlorophenyl)-[1,3]dioxolo[4,5-g]quinazoline (4s): Eluent: petroleum ether-ethyl acetate (20:1); yellow solid (97 mg, 68%), mp 220-221 °C (lit³. mp 224-226 °C); ¹H NMR (400 MHz, CDCl₃) δ : 6.16 (s, 2H), 7.10 (s, 1H), 7.31 (s, 1H), 7.46 (d, *J* = 8.0 Hz, 2H), 8.48 (d, *J* = 7.6 Hz, 2H), 9.13 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ : 101.9, 102.2, 105.0, 120.8, 128.7, 129.5, 136.4, 136.7, 148.4, 150.3, 154.3, 157.5, 159.1. IR (KBr) ν = 2914, 1478, 1224, 1038, 846, 795 cm⁻¹. MS: m/z 285 (MH)⁺.

2-(4-Chlorophenyl)-7-fluoroquinazoline (4t): Eluent: petroleum ether-ethyl acetate (20:1); white solid (87 mg, 67%), mp 139-141 °C; ¹H NMR (400 MHz, CDCl₃) δ : 7.37-7.42 (m, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.67-7.70 (m, 1H), 7.93-7.97 (m, 1H), 8.56 (d, *J* = 8.0 Hz, 2H), 9.42 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 112.4, 112.6, 118.0, 118.3, 120.9, 128.9, 129.7, 129.8, 130.0, 136.1, 137.3, 152.3, 159.9, 160.8, 164.8, 167.4. IR (KBr) ν = 2924, 1614, 1539, 1412, 746 cm⁻¹. MS: m/z 259 (MH)⁺. HRMS (ESI) calcd for C₁₄H₉ClFN₂: 259.0438 [M+H], found: 259.0430.

General procedure for the preparation of 1,2,3,4-tetrahydroquinazoline 5. To a tube containing a solution of 2-bromobenzyl bromide **1** (0.5 mmol) in DMSO (2 mL) were added aldehyde **2** (0.6 mmol), Cu(OAc)₂ (0.05 mmol), DMAP (0.15 mmol) and 40% aqueous methylamine or 65% aqueous ethylamine **3** (1 mL). Then, the tube was sealed and the mixture was stirred at 80 °C under air atmosphere for 14 h. After being cooled to room temperature, the reaction was quenched with NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with H₂O and brine, and then dried over anhydrous Na₂SO₄. The solvent was evaporated under vacuum and the crude product was purified by chromatography on silica-gel to afford 1,2,3,4-tetrahydroquinazoline derivatives **5**.



1,3-Dimethyl-2-phenyl-1,2,3,4-tetrahydroquinazoline (5a): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (81 mg, 67%); ¹H NMR (400 MHz, CDCl₃) δ: 2.56 (s, 3H; 3a-H), 2.98 (s, 3H; 1a-H), 3.42 (d, *J* = 15.6 Hz, 1H; 4-H), 3.84 (d, *J* = 16.0 Hz, 1H; 4-H), 4.91 (s, 1H; 2-H), 6.69-6.72 (m, 2H; 6-H and 8-H), 6.92 (d, *J* = 7.2 Hz, 1H; 5-H), 7.21-7.36 (m, 6H; 7-H, 10-H, 11-H, 12-H, 13-H, 14-H). ¹³C NMR (100 MHz, CDCl₃) δ: 36.7 (C-3a), 42.4 (C-1a), 49.3 (C-4), 82.1 (C-2), 108.9 (C-8), 115.9 (C-6), 117.9 (C-4a), 127.10 (C-10 and C-14), 127.13 (C-12), 127.8 (C-5), 127.9 (C-7), 128.5 (C-11 and C-13), 140.7 (C-9), 143.6 (C-8a). IR (KBr) ν = 2937, 1610, 1504, 1284, 745 cm⁻¹. MS: m/z 239 (MH)⁺. HRMS (ESI) calcd for C₁₆H₁₉N₂: 239.1548 [M+H], found: 239.1552.

2-(4-Methoxyphenyl)-1,3-dimethyl-1,2,3,4-tetrahydroquinazoline (5b): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (93 mg, 69%); ¹H NMR (400 MHz, CDCl₃) δ: 2.52 (s, 3H), 2.96 (s, 3H), 3.41 (d, *J* = 16.0 Hz, 1H), 3.79 (s, 3H), 3.83 (d, *J* = 15.6 Hz, 1H), 4.86 (s, 1H), 6.66-6.70 (m, 2H), 6.85-6.87 (m, 2H), 6.91 (d, *J* = 7.6 Hz, 1H), 7.16-7.26 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ: 36.6, 42.2, 49.3, 55.3, 81.6, 108.9, 113.8, 115.8, 117.9, 127.1, 127.9, 128.3, 132.8, 143.7, 159.2. IR (KBr) ν = 2978, 1616, 1523, 1284, 742 cm⁻¹. MS: m/z 269 (MH)⁺. HRMS (ESI) calcd for C₁₇H₂₁N₂O: 269.1654 [M+H], found: 269.1650.

2-(4-Bromophenyl)-1,3-dimethyl-1,2,3,4-tetrahydroquinazoline (5c): Eluent: petroleum ether-ethyl acetate (10:1); colourless liquid (111 mg, 70%); ^1H NMR (400 MHz, CDCl_3) δ : 2.51 (s, 3H), 2.95 (s, 3H), 3.38 (d, $J = 16.4$ Hz, 1H), 3.76 (d, $J = 16.4$ Hz, 1H), 4.83 (s, 1H), 6.66-6.69 (m, 2H), 6.89 (d, $J = 7.2$ Hz, 1H), 7.12 (d, $J = 8.4$ Hz, 2H), 7.19-7.22 (m, 1H), 7.43 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ : 36.8, 42.3, 49.2, 81.6, 109.0, 116.1, 117.8, 121.7, 127.2, 127.9, 128.9, 131.6, 139.9, 143.3. IR (KBr) $\nu = 2960, 1604, 1506, 1282, 743 \text{ cm}^{-1}$. MS: m/z 317 (MH^+). HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{18}\text{BrN}_2$: 317.0653 [M+H], found: 317.0655.

1,3-Dimethyl-2-(4-nitrophenyl)-1,2,3,4-tetrahydroquinazoline (5d): Eluent: petroleum ether-ethyl acetate (5:1); yellow liquid (98 mg, 69%); ^1H NMR (400 MHz, CDCl_3) δ : 2.54 (s, 3H), 3.00 (s, 3H), 3.40 (d, $J = 16.0$ Hz, 1H), 3.79 (d, $J = 16.0$ Hz, 1H), 4.94 (s, 1H), 6.68-6.73 (m, 2H), 6.89 (d, $J = 6.4$ Hz, 1H), 7.22 (t, $J = 7.2$ Hz, 1H), 7.42 (d, $J = 8.4$ Hz, 2H), 8.16 (d, $J = 8.4$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ : 37.0, 42.4, 49.2, 81.4, 109.3, 116.6, 117.6, 123.8, 127.3, 128.1, 134.4, 142.0, 143.0, 148.3. IR (KBr) $\nu = 2939, 1610, 1500, 1315, 745 \text{ cm}^{-1}$. MS: m/z 284 (MH^+). HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{O}_2$: 284.1399 [M+H], found: 284.1394.

1,3-Dimethyl-2-m-tolyl-1,2,3,4-tetrahydroquinazoline (5e): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (82 mg, 65%); ^1H NMR (400 MHz, CDCl_3) δ : 2.35 (s, 3H), 2.54 (s, 3H), 2.97 (s, 3H), 3.41 (d, $J = 15.2$ Hz, 1H), 3.86 (d, $J = 15.6$ Hz, 1H), 4.87 (s, 1H), 6.67-6.71 (m, 2H), 6.92 (d, $J = 6.8$ Hz, 1H), 7.02 (d, $J = 8.0$ Hz, 1H), 7.12 (s, 2H), 7.19-7.25 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ : 21.6, 36.7, 42.4, 49.4, 82.2, 108.8, 115.8, 117.9, 124.0, 127.1, 127.87, 127.89, 128.3, 128.6, 138.2, 140.8, 143.7. IR (KBr) $\nu = 2967, 1604, 1504, 1268, 745 \text{ cm}^{-1}$. MS: m/z 253 (MH^+). HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2$: 253.1704 [M+H], found: 253.1708.

2-(3-Fluorophenyl)-1,3-dimethyl-1,2,3,4-tetrahydroquinazoline (5f): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (86 mg, 67%); ^1H NMR (400 MHz, CDCl_3) δ : 2.51 (s, 3H), 2.97 (s, 3H), 3.39 (d, $J = 16.4$ Hz, 1H), 3.78 (d, $J = 16.0$ Hz, 1H), 4.86 (s, 1H), 6.67 (t, $J = 8.0$ Hz, 2H), 6.89 (d, $J = 7.2$ Hz, 1H), 6.95 (d, $J = 8.4$ Hz, 2H), 7.02 (d, $J = 7.6$ Hz, 1H), 7.18-7.25 (m, 1H), 7.27-7.30 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 29.7, 36.8, 42.3, 49.2, 81.6, 109.0, 113.9, 114.2, 114.6, 114.8,

116.1, 117.7, 122.6, 122.7, 127.1, 127.9, 129.9, 130.0, 143.2, 143.7, 164.2. IR (KBr) ν = 2960, 1598, 1501, 1273, 743 cm⁻¹. MS: m/z 257 (MH)⁺. HRMS (ESI) calcd for C₁₆H₁₈FN₂: 257.1454 [M+H], found: 257.1459.

1,3-Dimethyl-2-o-tolyl-1,2,3,4-tetrahydroquinazoline (5g): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (90 mg, 71%); ¹H NMR (400 MHz, CDCl₃) δ : 2.48 (s, 3H), 2.55 (s, 3H), 2.91 (s, 3H), 3.36 (d, *J* = 16.0 Hz, 1H), 3.88 (d, *J* = 16.0 Hz, 1H), 4.96 (s, 1H), 6.68 (t, *J* = 6.8 Hz, 2H), 6.92 (d, *J* = 7.2 Hz, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 7.06-7.10 (m, 1H), 7.20-7.26 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 18.8, 36.3, 42.3, 49.1, 79.6, 108.3, 115.6, 117.6, 125.5, 126.1, 127.1, 127.6, 127.9, 131.0, 136.6, 138.6, 144.0. IR (KBr) ν = 2931, 1604, 1504, 1280, 743 cm⁻¹. MS: m/z 253 (MH)⁺. HRMS (ESI) calcd for C₁₇H₂₁N₂: 253.1704 [M+H], found: 253.1696.

1,3-Dimethyl-2-(naphthalen-1-yl)-1,2,3,4-tetrahydroquinazoline (5h): Eluent: petroleum ether-ethyl acetate (10:1); white solid (93 mg, 64%), mp 147-149 °C; ¹H NMR (400 MHz, CDCl₃) δ : 2.73 (s, 3H), 3.03 (s, 3H), 3.44 (d, *J* = 15.6 Hz, 1H), 3.93 (d, *J* = 15.6 Hz, 1H), 5.59 (s, 1H), 6.74-6.81 (m, 2H), 6.97 (d, *J* = 8.0 Hz, 1H), 7.25 (d, *J* = 6.8 Hz, 1H), 7.32 (t, *J* = 8.0 Hz, 1H), 7.38 (t, *J* = 8.0 Hz, 1H), 7.55-7.59 (m, 1H), 7.63-7.67 (m, 1H), 7.83 (d, *J* = 8.0 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 36.6, 42.2, 49.5, 79.9, 108.4, 115.8, 117.4, 124.2, 124.3, 125.0, 125.7, 126.4, 127.4, 128.0, 128.7, 128.8, 131.2, 134.4, 135.3, 144.0. IR (KBr) ν = 2935, 2894, 1605, 1504, 1296, 748 cm⁻¹. MS: m/z 289 (MH)⁺. HRMS (ESI) calcd for C₂₀H₂₁N₂: 289.1704 [M+H], found: 289.1708.

1,3-Dimethyl-2-(thiophen-2-yl)-1,2,3,4-tetrahydroquinazoline (5i): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (67 mg, 55%); ¹H NMR (400 MHz, CDCl₃) δ : 2.52 (s, 3H), 3.05 (s, 3H), 3.51 (d, *J* = 16.4 Hz, 1H), 4.01 (d, *J* = 16.4 Hz, 1H), 5.13 (s, 1H), 6.68-6.72 (m, 2H), 6.83-6.84 (m, 1H), 6.91-6.93 (m, 2H), 7.19-7.26 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ : 37.1, 41.6, 49.6, 78.5, 109.6, 116.5, 118.1, 125.4, 125.5, 126.5, 127.0, 127.8, 142.8, 144.4. IR (KBr) ν = 2937, 2877, 1605, 1504, 1283, 747 cm⁻¹. MS: m/z 245 (MH)⁺. HRMS (ESI) calcd for C₁₄H₁₇N₂S: 245.1112 [M+H], found: 245.1116.

1,3-Dimethyl-1,2,3,4-tetrahydroquinazoline (5j): Eluent: petroleum ether-ethyl acetate (5:1); colourless liquid (72 mg, 88%); ^1H NMR (400 MHz, CDCl_3) δ : 2.50 (s, 3H), 2.87 (s, 3H), 3.83 (s, 2H), 3.90 (s, 2H), 6.65-6.71 (m, 2H), 6.92 (d, J = 7.6 Hz, 1H), 7.13 (t, J = 7.2 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 36.8, 41.6, 55.8, 73.0, 111.4, 117.2, 120.0, 126.9, 127.5, 145.0. IR (KBr) ν = 2926, 1663, 1606, 1504, 749 cm^{-1} . MS: m/z 163 (MH^+). HRMS (ESI) calcd for $\text{C}_{10}\text{H}_{15}\text{N}_2$: 163.1235 [M+H], found: 163.1236.

1,2,3-Trimethyl-1,2,3,4-tetrahydroquinazoline (5k): Eluent: petroleum ether-ethyl acetate (5:1); colourless liquid (75 mg, 85%); ^1H NMR (400 MHz, CDCl_3) δ : 1.24 (d, J = 6.4 Hz, 3H), 2.45 (s, 3H), 2.88 (s, 3H), 3.55 (d, J = 16.8 Hz, 1H), 3.92-3.97 (m, 1H), 4.27 (d, J = 16.8 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 6.66 (t, J = 7.2 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 16.2, 35.7, 42.2, 48.9, 74.9, 110.3, 116.1, 117.4, 127.0, 127.6, 143.0. IR (KBr) ν = 2934, 1604, 1501, 1290, 746 cm^{-1} . MS: m/z 177 (MH^+). HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{17}\text{N}_2$: 177.1391 [M+H], found: 177.1398.

2-Benzyl-1,3-dimethyl-1,2,3,4-tetrahydroquinazoline (5l): Eluent: petroleum ether-ethyl acetate (5:1); colorless liquid (104 mg, 82%); ^1H NMR (400 MHz, CDCl_3) δ : 2.47 (s, 3H), 2.76 (s, 3H), 2.99 (d, J = 6.4 Hz, 2H), 3.63 (d, J = 16.8 Hz, 1H), 4.07 (t, J = 6.4 Hz, 1H), 4.51 (d, J = 16.4 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.78 (t, J = 7.2 Hz, 1H), 7.06 (d, J = 7.2 Hz, 1H), 7.24-7.40 (m, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ : 37.8, 39.0, 42.7, 49.2, 81.6, 110.3, 116.1, 117.1, 126.4, 127.3, 127.8, 128.5, 129.6, 138.7, 142.8. IR (KBr) ν = 2932, 1604, 1504, 1286, 747 cm^{-1} . MS: m/z 253 (MH^+). HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2$: 253.1704 [M+H], found: 253.1711.

5,7-Dimethyl-6-phenyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]quinazoline (5m): Eluent: petroleum ether-ethyl acetate (10:1); colourless liquid (105 mg, 74%); ^1H NMR (400 MHz, CDCl_3) δ : 2.51 (s, 3H), 2.92 (s, 3H), 3.31 (d, J = 16.4 Hz, 1H), 3.72 (d, J = 15.2 Hz, 1H), 4.81 (s, 1H), 5.85 (s, 2H), 6.36 (s, 1H), 6.44 (s, 1H), 7.21-7.23 (m, 2H), 7.26-7.33 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ : 37.4, 42.2, 49.5, 81.9, 92.3, 100.3, 107.6, 109.6, 127.1, 127.8, 128.4, 138.0, 138.9, 140.6, 147.2. IR

(KBr) ν = 2928, 1504, 1235, 1039, 749 cm⁻¹. MS: m/z 283 (MH)⁺. HRMS (ESI) calcd for C₁₇H₁₈N₂NaO₂: 305.1266 [M+Na], found: 305.1252.

5-Chloro-1,3-dimethyl-2-phenyl-1,2,3,4-tetrahydroquinazoline (5n): Eluent: petroleum ether-ethyl acetate (10:1); yellow syrup (104 mg, 76%); ¹H NMR (400 MHz, CDCl₃) δ : 2.56 (s, 3H), 3.01 (s, 3H), 3.65 (d, *J* = 16.4 Hz, 1H), 3.76 (d, *J* = 16.4 Hz, 1H), 4.93 (s, 1H), 6.62 (d, *J* = 7.6 Hz, 1H), 6.71-6.74 (m, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 7.22-7.26 (m, 2H), 7.30-7.36 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ : 37.2, 42.6, 47.1, 81.7, 107.4, 115.6, 116.6, 127.0, 128.0, 128.2, 128.6, 133.2, 140.1, 145.0. IR (KBr) ν = 2935, 1593, 1487, 1284, 761 cm⁻¹. MS: m/z 273 (MH)⁺. HRMS (ESI) calcd for C₁₆H₁₇ClN₂Na: 295.0978 [M+Na], found: 295.0983.

Methyl 1,3-dimethyl-2-phenyl-1,2,3,4-tetrahydroquinazoline-6-carboxylate (5o): Eluent: petroleum ether-ethyl acetate (10:1); colorless liquid (101 mg, 68%); ¹H NMR (400 MHz, CDCl₃) δ : 2.51 (s, 3H), 3.01 (s, 3H), 3.40 (d, *J* = 16.0 Hz, 1H), 3.78 (d, *J* = 16.0 Hz, 1H), 3.84 (s, 3H), 4.94 (s, 1H), 6.66 (d, *J* = 8.4 Hz, 1H), 7.18-7.20 (m, 2H), 7.28-7.34 (m, 3H), 7.59 (s, 1H), 7.90 (dd, *J*₁ = 8.4 Hz, *J*₂ = 2.0 Hz 1H). ¹³C NMR (100 MHz, CDCl₃) δ : 36.8, 42.2, 48.6, 51.5, 82.2, 108.0, 116.8, 117.0, 126.8, 128.2, 128.6, 128.8, 130.4, 139.8, 147.3, 167.5. IR (KBr) ν = 2944, 1709, 1610, 1517, 1296, 768 cm⁻¹. MS: m/z 297 (MH)⁺. HRMS (ESI) calcd for C₁₈H₂₁N₂O₂: 297.1603 [M+H], found: 297.1611.

1,3-Diethyl-2-phenyl-1,2,3,4-tetrahydroquinazoline (5p): Eluent: petroleum ether-ethyl acetate (10:1); colourless liquid (85 mg, 64%); ¹H NMR (400 MHz, CDCl₃) δ : 1.17-1.26 (m, 6H), 2.58-2.71 (m, 2H), 3.04-3.13 (m, 1H), 3.44 (d, *J* = 16.4 Hz, 1H), 3.56-3.65 (m, 1H), 3.77 (d, *J* = 16.4 Hz, 1H), 5.05 (s, 1H), 6.60 (t, *J* = 7.2 Hz, 1H), 6.70 (d, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 6.4 Hz, 1H), 7.17 (t, *J* = 7.6 Hz, 1H), 7.24-7.29 (m, 5H). ¹³C NMR (100 MHz, CDCl₃) δ : 12.2, 13.4, 29.7, 42.8, 47.1, 77.6, 108.4, 115.1, 117.4, 127.3, 127.4, 127.6, 127.7, 128.3, 138.8, 142.6. IR (KBr) ν = 2968, 1610, 1504, 1274, 745 cm⁻¹. MS: m/z 267 (MH)⁺. HRMS (ESI) calcd for C₁₈H₂₃N₂: 267.1861 [M+H], found: 267.1866.

2-(3-Chlorophenyl)-1,3-diethyl-1,2,3,4-tetrahydroquinazoline (5q): Eluent: petroleum ether-ethyl acetate (10:1); colourless liquid (101 mg, 70%); ¹H NMR (400 MHz, CDCl₃) δ : 1.19-1.26 (m, 6H), 2.57-2.72 (m, 2H), 3.02-3.11 (m, 1H), 3.46 (d, *J* = 16.0 Hz, 1H), 3.61-3.70 (m, 1H), 3.76 (d, *J* = 16.4

Hz, 1H), 5.01 (s, 1H), 6.63 (t, J = 7.2 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 6.8 Hz, 1H), 7.17-7.26 (m, 4H), 7.33 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 12.1, 13.4, 42.8, 47.1, 77.3, 108.6, 115.4, 117.5, 125.5, 127.5, 127.6, 127.7, 127.8, 129.6, 134.3, 142.2, 144.3. IR (KBr) ν = 2968, 1604, 1503, 1273, 743 cm^{-1} . MS: m/z 301 (MH^+). HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{22}\text{ClN}_2$: 301.1471 [M+H], found: 301.1477.

1,3-Diethyl-1,2,3,4-tetrahydroquinazoline (5r): Eluent: petroleum ether-ethyl acetate (5:1); colorless liquid (82 mg, 86%); ^1H NMR (400 MHz, CDCl_3) δ : 1.15-1.21 (m, 6H), 2.63 (q, J = 7.2 Hz, 2H), 3.32 (q, J = 7.2 Hz, 2H), 3.89 (s, 2H), 4.06 (s, 2H), 6.61-6.65 (m, 2H), 6.91 (d, J = 6.8 Hz, 1H), 7.07-7.12 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ : 11.9, 13.0, 43.5, 47.0, 53.8, 68.5, 110.7, 116.3, 119.5, 127.3, 127.5, 143.8. IR (KBr) ν = 2968, 1605, 1504, 1271, 745 cm^{-1} . MS: m/z 191 (MH^+). HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{18}\text{N}_2\text{Na}$: 213.1368 [M+Na], found: 213.1374.


Procedure for the preparation of 1-methyl-2-phenyl-1,2,3,4-tetrahydroquinazoline (7). To a tube containing a solution of 2-bromobenzyl amine **6** (0.5 mmol) in DMSO (2 mL) were added benzaldehyde **2a** (0.6 mmol), $\text{Cu}(\text{OAc})_2$ (0.05 mmol), DMAP (0.15 mmol) and 40% aqueous methylamine **3b** (1 mL). Then, the tube was sealed and the mixture was stirred at 80 °C under air atmosphere for 12 h. After being cooled to room temperature, the reaction was quenched with NH_4Cl solution and extracted with ethyl acetate. The combined organic layers were washed with H_2O and brine, and then dried over anhydrous Na_2SO_4 . The solvent was evaporated under vacuum and the crude product was purified by chromatography on silica-gel to afford **7**.


1-Methyl-2-phenyl-1,2,3,4-tetrahydroquinazoline (7): Eluent: petroleum ether-ethyl acetate (5:1); colorless liquid (87 mg, 78%); ^1H NMR (400 MHz, CDCl_3) δ : 2.86 (s, 3H), 3.75 (d, J = 16.8 Hz, 1H), 3.86 (d, J = 16.0 Hz, 1H), 5.22 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.30-7.39 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3) δ : 35.9, 43.4, 75.8, 110.5, 116.0, 122.3, 125.4, 127.2, 127.9, 128.6, 141.1, 145.0. IR (KBr) ν = 2937, 1603, 1501, 1284, 743 cm^{-1} . MS: m/z 225 (MH^+). HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2$: 225.1391 [M+H], found: 225.1382.


Procedure for the preparation of *N*-methyl-2-((methylamino)methyl)aniline (8). To a tube containing a solution of 2-bromobenzyl bromide **1a** (0.5 mmol) in DMSO (2 mL) were added Cu(OAc)₂ (0.05 mmol), DMAP (0.15 mmol) and 40% aqueous methylamine **3b** (1 mL). Then, the tube was sealed and the mixture was stirred at 80 °C under air for 12 h. After being cooled to room temperature, the reaction was quenched with NH₄Cl solution and extracted with ethyl acetate. The combined organic layers were washed with H₂O and brine, and then dried over anhydrous Na₂SO₄. The solvent was evaporated under vacuum and the crude product was purified by chromatography on silica-gel to afford **8**.


***N*-Methyl-2-((methylamino)methyl)aniline (8):** Eluent: petroleum ether-ethyl acetate (1:1); colorless liquid (64 mg, 85%); ¹H NMR (400 MHz, CDCl₃) δ: 2.44 (s, 3H), 2.87 (s, 3H), 3.76 (s, 2H), 6.67 (t, *J* = 8.0 Hz, 2H), 7.06 (d, *J* = 7.6 Hz, 1H), 7.24 (t, *J* = 8.0 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ: 30.2, 6.0, 55.4, 109.6, 116.0, 123.6, 128.7, 129.6, 149.4. IR (KBr) ν = 2924, 1652, 1591, 1264, 758 cm⁻¹. MS: m/z 151 (MH)⁺. HRMS (ESI) calcd for C₉H₁₅N₂: 151.1235 [M+H], found: 151.1238.


III. Copies of ^1H and ^{13}C NMR spectra of 4a-4t





























































IV. Copies of ^1H and ^{13}C NMR spectra of 5a-5r




















































V. Copies of ^1H and ^{13}C NMR spectra of 7



VI. Copies of ^1H and ^{13}C NMR spectra of 8



VII. References

- [1] C. Wang, S. Li, H. Liu, Y. Jiang, H. Fu, *J. Org. Chem.* **2010**, *75*, 7936-7938.
- [2] B. Han, X. L. Yang, C. Wang, Y. M. Bai, T. C. Pan, X. Chen, W. Yu, *J. Org. Chem.* **2012**, *77*, 1136-1142.
- [3] C. C. Malakar, A. Baskakova, J. Conrad, U. Beifuss, *Chem. Eur. J.* **2012**, *18*, 8882-8885.